Trial Profile

A clinical study of R-107 in patients with Severe COVID-19 Pneumonia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R 107 Radikal Therapeutics (Primary)
Indications COVID-19 pneumonia
Focus Therapeutic Use

Most Recent Events

09 Aug 2021 New trial record
26 Jul 2021 According to a Claritas Pharmaceuticals media release, this study was led by clinicians at Royal Brompton & Harefield NHS Foundation Trust.
26 Jul 2021 Results published in the Claritas Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com